New Grant: Award Supports Development of Artificial Immunotherapy Cells for Fighting Cancer
Sept. 22, 2022 - Principal investigators: Abraham Lee, Chancellor’s Professor of biomedical engineering and director of the Center for Advanced Design and Manufacturing of Integrated Microfluidics, and Anshu Agrawal, professor of medicine
Award: $1.13 million over three years
Funding agency: National Institutes of Health – National Cancer Institute (1R33CA267258-01A1)
Project: Microfluidic Precision Engineered Artificial Antigen Presenting Cells for Cancer Immunotherapy
The goal of cancer immunotherapy is to build long-lasting tumor-specific immunologic “memory” in patients that enables the lifelong rejection of tumors. However, immunotherapy of cancer using cells is an expensive and cumbersome process. One critical question is how to generate, within a short period of time, large numbers of antitumor T cells. The present project aims at developing artificial cells that can be produced inexpensively via microfluidic engineering-based methods. These artificial cells will be developed to activate T cells in vivo to boost their capability to fight cancer.
– Rachel Karas